Taylor Weuve, LAT, ATC in Vienna, VA - Preventive Medicine

Taylor Weuve, LAT, ATC is a Preventive Medicine - Sports Medicine physician based in Vienna, Virginia. Taylor Weuve is licensed to practice in Virginia (license number 0126003055) and her current practice location is 2500 James Madison Dr, Vienna, Virginia. She can be reached at her office (for appointments etc.) via phone at (703) 319-2300.

NPI number for Taylor Weuve is 1780128892 and her current mailing address is 2500 James Madison Dr, Vienna, Virginia. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1780128892.

Contact Information

	Taylor Weuve, LAT, ATC
	2500 James Madison Dr, Vienna, VA 22181-5599
	(703) 319-2300
	Not Available

Physician's Profile

Full Name	Taylor Weuve
Gender	Female
Speciality	Preventive Medicine - Sports Medicine
Location	2500 James Madison Dr, Vienna, Virginia
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1780128892
Provider Enumeration Date: 12/08/2016
Last Update Date: 05/14/2020

Medical Identifiers

Medical identifiers for Taylor Weuve such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1780128892	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
2083S0010X	Preventive Medicine - Sports Medicine	0126003055 (Virginia)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Taylor Weuve is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Taylor Weuve, LAT, ATC 2500 James Madison Dr, Vienna, VA 22181-5599 Ph: () -	Taylor Weuve, LAT, ATC 2500 James Madison Dr, Vienna, VA 22181-5599 Ph: (703) 319-2300

News Archive

FDA approves first drug for patients with hypereosinophilic syndrome in nearly 14 years

Today, the U.S. Food and Drug Administration approved Nucala (mepolizumab) for adults and children aged 12 years and older with hypereosinophilic syndrome (HES) for six months or longer without another identifiable non-blood related cause of the disease.

Gene therapy may prevent the damaging effects of radiation

Gene therapy could be used as an agent to protect normal tissues, including the esophagus and lung, from damage during a second administration of radiation therapy for non-small cell lung cancer, according to an animal study presented by University of Pittsburgh researchers at the 47th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO) in Denver.

Researchers to develop high-precision computer models that can predict epidemic risk

Software "agents" modelled on real-life individuals will be used by University of Sydney researchers to develop high-precision computer models that can predict where or when an epidemic may strike.

Roche receives FDA approval for CMV viral load test

The U.S. Food and Drug Administration today approved the first DNA test to help health care professionals gauge the progress of anti-viral treatment in solid organ transplant patients undergoing cytomegalovirus (CMV) antiviral therapy.

Taylor Weuve, LAT, ATC - Preventive Medicine in Vienna, VA